^
    2d
    Genetic characterization of pediatric B-cell acute lymphoblastic leukemia in Argentina uncovers molecular heterogeneity and novel variants. (PubMed, Front Pharmacol)
    Importantly, we identified novel single nucleotide variants in DUX4, CSF3R and CREBBP, and fusion transcripts. This study not only reports transcriptional heterogeneity in our Latin American cohort but also supports the implementation of open-source bioinformatic pipelines in resource-limited settings to enhance precision diagnosis and guide personalized treatment.
    Journal
    |
    CREBBP (CREB binding protein) • CSF3R (Colony Stimulating Factor 3 Receptor) • DUX4 (Double Homeobox 4)
    2d
    Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia. (PubMed, Clin Lymphoma Myeloma Leuk)
    Our results support a dual approach: HSCT for patients with high-risk cytogenetics or MRD positivity, and MRD-guided therapy for those not eligible for transplant. These findings reinforce risk-adapted strategies and lay the groundwork for future trials combining genetic and MRD-guided management in Ph- B-ALL.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    2d
    AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate)
    3d
    Allogeneic UCB-derived CAR-T for B-ALL (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, The General Hospital of Western Theater Command
    New P1 trial
    4d
    "Upfront Use of Blinatumomab in Adolescents and Adults With Philadelphia Chromosome: Negative B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Proportional Meta-Analysis". (PubMed, Clin Lymphoma Myeloma Leuk)
    Variations in OS appear driven by patient heterogeneity and concurrent chemotherapy intensity rather than blinatumomab timing. Future studies should refine its integration within targeted and genomically defined strategies, particularly for high-risk subsets such as Ph-like and KMT2A-rearranged B-ALL.
    Retrospective data • Review • Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    Blincyto (blinatumomab)
    6d
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T
    8d
    A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity. (PubMed, Haematologica)
    Furthermore, cell-free and cellular thermal shift assays as well as drug affinity responsive target stability assays support on target activity of I3IN-002 for IGF2BP3. Thus, the identification of I3IN-002 paves the way for the discovery of potent and selective small molecule inhibitors of IGF2BP3.
    Journal
    |
    IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    9d
    Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China. (PubMed, Curr Oncol)
    This study delineated the genetic landscape of pAML in Southwest China and explored the prognostic value of gene fusions and mutations in early and long-term outcomes. These findings provide a foundation for understanding the genetic heterogeneity of pAML and offer evidence for the development of precision medicine approaches.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    FLT3-ITD mutation • KIT mutation • KMT2A rearrangement
    10d
    Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL (clinicaltrials.gov)
    P2, N=59, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P2 trial
    |
    S1904
    10d
    KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=30, Recruiting, Zhejiang University
    New P1 trial
    10d
    NCI-2018-02016: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=37, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participation
    Trial termination
    |
    CD22 (CD22 Molecule)
    |
    epratuzumab-cys-tesirine (ADCT-602)
    11d
    PD-1 Expression Promotes Immune Evasion in B-ALL. (PubMed, Hematol Rep)
    These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • PAX5 (Paired Box 5)